D1.272 - Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom

Anaphylaxis is a life-threatening systemic allergic reaction often accompanied by manifestations in the skin and mucous membranes.This study aimed to evaluate the efficacy and safety of Omalizumab in the treatment of anaphylaxis patients presenting with urticaria as the initial symptom.

A retrospective study was conducted on Chinese patients with anaphylaxis who receive Omalizumab in the Department of Allergy, Affiliated Hospital of Qingdao University from January 2020 to June 2024.The patients were divided into two groups based on the presence or absence of loss of consciousness during episodes: mild-to-moderate and severe.Follow-up evaluations post-OMA treatment assessed reaction frequency and adverse events, analyzing the impact of medical history, disease severity, and treatment duration on outcomes.

65 patients were included, with an average age of 34.77±16.36 years. 55 patients had urticaria history, 53 were chronic urticaria sufferers. Treatment duration averaged 6 (3, 9.75) months. 10 patients discontinued after one injection, while 45 (69.23%) completed at least 3 months of treatment. 4 patients (7.3%) experienced relapse post-treatment cessation. Relapsing patients often had other allergies (42.3% vs. 18.8%, p = 0.029). Upon restarting Omalizumab, relapsing patients achieved disease control. Of 635 injections, 32 (5.04%) resulted in local reactions, managed without systemic issues.

OMA is effective and safe for severe allergic reactions with urticaria as the initial symptom, showing promise in treatment and prevention.